pubmed.ncbi.nlm.nih.gov
Systems pharmacology reveals type I interferon and myeloid-like B cell reprogramming as candidate druggable axes in antiphospholipid syndrome - PubMed
Antiphospholipid syndrome (APS) lacks disease-modifying targeted therapies, and its molecular heterogeneity remains poorly characterized. We employed an integrative systems pharmacology approach combining weighted gene co-expression network analysis (WGCNA), single-cell RNA sequencing, Connectivity …